Aquinox Pharmaceuticals (AQXP) Downgraded to “Hold” at Zacks Investment Research
Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
AQXP has been the subject of a number of other reports. Canaccord Genuity restated a “buy” rating and set a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Finally, ValuEngine lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $22.00.
Several institutional investors have recently added to or reduced their stakes in AQXP. Nexthera Capital LP purchased a new stake in shares of Aquinox Pharmaceuticals during the second quarter worth $1,276,000. University of Notre Dame DU Lac grew its holdings in shares of Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after buying an additional 19,066 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Aquinox Pharmaceuticals during the third quarter worth $194,000. Finally, Sphera Funds Management LTD. grew its holdings in shares of Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after buying an additional 13,450 shares in the last quarter. 96.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals (AQXP) Downgraded to “Hold” at Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/12/aquinox-pharmaceuticals-aqxp-downgraded-to-hold-at-zacks-investment-research.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.